Autolus Provides Update on CAR-T Program; Q1 2020 Call Summary
On Thursday, May 7, Autolus held their Q1 2020 earnings call (press release / presentation), highlighting their current clinical progress, enrollment, and potential initiation of their pivotal trial AUTO1-AL1 in adult r/r ALL. Below, Celltelligence provides thoughts on Autolus’s cell therapy program, particularly in the context of the ongoing health emergency.
About The Author
The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.
If you receive our email blasts, you already have an account. Log in now
You’ll be able to access the full article from your Celltelligence Library after signing up.